There’s A 14% Slump Ahead For AstraZenenca plc

Recovery might be coming for AstraZeneca plc (LON: AZN), but it’ll take a few more years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since Pascal Soriot took the helm at AstraZeneca (LSE: AZN) (NYSE: AZN.US) in October 2012, investor confidence has been returning strongly. The share price is up 23% over the past 12 months, to 4,175p, and over three years it has picked up 35% against the FTSE’s 10% — and that’s impressive for a company that has seen earnings falling for two years in a row.

Earnings falling

AZNIn fact, earnings per share (EPS) slumped by 26% in 2013, in part due to the expiry of patents on some key drugs and increasing competition from generic alternatives.

With the shares on the rise again, you might think there’s a return to growth forecast. Well, no, there isn’t. The current consensus still suggests a further 14% fall in earnings for 2014, with a 2% slip to follow in 2015 — and that puts the shares on a forward P/E for 2015 of 16, which some will see as a bit high.

And we must remember that forecasts for rival GlaxoSmithKline, which faces the same industry problems, are looking a good bit better.

Past the bottom?

The trend of forecasts for AstraZeneca has been slipping, too. The same analysts who are now predicting 2014 EPS of 258p were touting 335p just a year ago, but at least it has firmed up a little in the past month, from a low of 255p.

Forecasts for 2015 have also started to reverse their downward movement, as updates from the company have started sounding a bit more bullish — as recently as last week, speaking of first-quarter results, Mr Soriot said “We are investing in our rapidly progressing pipeline and the key platforms that are the backbone of our strategy to return to growth“.

Against that optimism, however, there’s still a wide spread of opinions between individual analysts’ forecasts — though we’re awaiting adjustments after that first-quarter update.

ThumbDownOn the actual recommendation front, out of a sample of 32 commentators, five have posted Buy recommendations with 11 suggesting Sell. That puts a fairly large proportion of them in the remaining 15 who are sitting on the Hold fence — presumably waiting for concrete news before endorsing (or refuting) the company’s upbeat outlook.

Wait and see

What do I think? Well, GlaxoSmithKline looks the better investment to me right now, with better earnings and dividend forecasts, a lower P/E valuation, and that positive-looking Novartis deal in the bag.

On the whole, then, I’m with the “wait and see” crowd, and I think the short-term optimism might be overdone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan does not own any shares in AstraZeneca or GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

The FTSE 100’s newest member looks like a no-brainer to me!

This Fool explains why she sees the newest member of the FTSE 100 as a great opportunity after its recent…

Read more »

Investing Articles

Empty Stocks and Shares ISA? Here’s how I’d start earning a second income from scratch

Like the thought of earning extra cash tax free? Our writer explains what he'd do to begin earning passive income…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

Up 35% from this year’s low! Here’s where I think Lloyds shares are headed in H2 of 2024

My Lloyds shares are already doing well this year but that’s not guaranteed to continue. What factors could turn the…

Read more »

Investing Articles

Approaching £5, is there still growth ahead for the Rolls-Royce share price?

The Rolls-Royce share price has been flying in the last year. But is there more growth ahead or should investors…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

Could Raspberry Pi be a growth share to buy and hold?

Our writer explains why he thinks a newly-listed UK growth share could have a bright future -- and considers whether…

Read more »

A pastel colored growing graph with rising rocket.
Market Movers

The FTSE 100 jumps after the Bank of England meeting. Here’s what’s next

Jon Smith runs over the takeaways from the Bank of England meeting today and flags up which FTSE 100 stocks…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

How I’d start investing in great value UK shares with £10,000 today

Harvey Jones can see a heap of UK shares he'd like to add to an ISA today. Many combine low…

Read more »